Jamali, Fakhreddin - University of Alberta - Department of Pharmaceutical Sciences

个人简介

Dr. Jamali (Doctor of Pharmacy, University of Tehran; MSc, pharmaceutics and PhD, pharmacokinetics, University of British Columbia) is a professor at the Faculty of Pharmacy and Pharm. Sci., University of Alberta. He joined the faculty at the University of Alberta in 1981. Dr. Jamali has served as a principal investigator with the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research and also with the Canadian Arthritis Network (Networks of Centres of Excellence, served as a Theme Leader). He has served as an honorary professor at the Science University of Tokyo (2010-14). For his academic achievements and research, he has been appointed is a Fellow of the Canadian Soc. Pharm. Sci (CSPS), the American Assoc. Pharm. Sci., and the American College of Clin. Pharmacology. He has received the Killam Professorship, McKeen Cattel Memorial Award of the American College of Clin. Pharmacol., the McCalla Professorship of the University of Alberta, the McNeil Award of Assoc Canadian Faculties of Pharm., CSPS/DuPond Leadership Award. For his service to the public he has been honored with the Alberta Centennial Medal and the Alberta Pharmacy Centennial Award of Distinction. He has been an invited speaker at many conferences. Dr. Jamali has served as an expert witness as well as consultant and/or a member of the board of directors of many pharmaceutical houses. He has been a member of the Health Canada’s TPP Expert Advisory Committee on Bioavailabilty and Bioequivalence, and the Expert Advisory Panel on Nonsteroidal Anti-imflammatory Drugs. He is the founding president of the Canadian Society for Pharmaceutical Sciences and founding editor of J. Pharm. & Pharm. Sci. (www.cspsCanada.org), the first open access, fully electronic peer-reviewed journal in the field. Has served as associate editor or in editorial board of several journals.

研究领域

Dr. Jamali's research interests include effect of pathophysiological changes on the action and disposition of drugs, stereochemical aspects of drugs action and disposition, basic and clinical pharmacology of anti-rheumatic, analgesic and cardiovascular drugs, and toxicology of nonsteroidal antiinfammatory drugs. He has trained 36 PhDs and published many refereed articles (H-Score, 42).

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

W Asghar, F Jamali (2015) The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology.23(1):1-16. doi: 10.1007/s10787-014-0225-9. W Asghar, E Pittman, F Jamali (2015) Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Daru J Pharrm Sci. .23:50, 1-7. doi: 10.1186/s40199-015-0133-6. A Aghazadeh-Habashi, W Asghar, F Jamali (2015) Simultaneous determination of selected eicosanoids by reversed-phase HPLC method using fluorescence detection and application to rat and human plasma, and rat heart and kidney samples. J Pharm Biomed Anal. 110:12-9. doi: 10.1016. A Aghazadeh-Habashi, MH Gilzad-Kohan , W Asghar, F Jamali (2014) Glucosamine Dose/Concentration-Effect Correlation in the Rat with Adjuvant Arthritis. J Pharm Sci. 103:760-767. S Harirforoosh, W Asghar, F Jamali (2013) Adverse Effects of Nonsteroidal Anti-inflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 16: 821-847. A Aghazadeh-Habashi, F Jamali (2011) The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci, 14: 264 - 273, 2011. F Sanaee; F Jamali (2014) Action and disposition of the β3-agonist nebivolol in presence of inflammation; an alternative to conventional β1-blockers. Current Pharmaceutical Design. Special issue on Cardio-metabolic Complication. Curr Pharm Des. 2014: 20(9):1311-7. F Sanaee, JD Clements, AWG Waugh, RN Fedorak, R Lewanczuk, F Jamali (2011) Crohn’s Disease elevates plasma concentrations of S-verapamil but reduces response to the drug proportional to disease activity. Brit J Clin Pharmacol, 72:787-97. F Jamali (2007) Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med 167: 2371-2. S Hanafy, N Dagenais, WF Dryden, F Jamali (2007) The effects of Angiotensin II receptor type I blockade on Inflammation-Induced Alterations of Pharmacokinetics and Pharmacodynamics of calcium channel blockers. Brit J Pharmacol 153: 90-99. KM Kulmatycki, F Jamali. (2006)R Drug disease interactions: Role of inflammatory mediators in depression and variability in drug response. J Pharm Pharm Sci, 9:292-306. N Daneshtalab, RZ Lewanczuk, AS Russell, F Jamali (2006) Losartan Effect Is Not Down-Regulated by Rheumatoid Arthritis. J Clin Pharmacol, 46:1344-1355. N Dagenais, F Jamali (2005) Protective Effects of Angiotensin II Interruption: Evidence for Anti-inflammatory Actions. Pharmacotherapy, 25:1213-29. S Harirforoosh, A Aghazadeh-Habashi, Fakhreddin Jamali* (2006) The extent of renal effect of COX-2-selective inhibitors is pharmacokinetic-dependent. Clinical and Experimental Pharmacology and Physiology. 33: 917-924. PR Mayo, K Skeith, AS Russell, F Jamali (2000) Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605-13. LA Eliot, F Jamali (1999) Pharmacokinetics and Pharmacodynamics of Nifedipine in Atorvastatin Treated Hyperlipidemia in the Rat. J Pharmacol Exp Ther, 291:188-193. F Jamali* CM Kunz (1999) Pain-Mediated altered Absorption and Metabolism: An Explanation for Delayed Onset of Analgesia. Br J Clin Pharmacol, 47:391-396. F Jamali (1992) Enantioselective versus non-enantioselective assays in comparative bioavailability studies with racemic drugs. Biopharm Drug Dispos, 13: 385-387. F Jamali; R Mehvar; FM Pasutto (1989) Stereospecific Aspects of Drug Action and Disposition: Therapeutic Pitfalls. J Pharm Sci, 78: 695 715.